{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:04:02Z","timestamp":1789535042647,"version":"build-2803163510"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mixed-phenotype acute leukemia (MPAL) has a poor prognosis, and initial presentation with cauda equina syndrome (CES) is extremely rare. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be the only potentially curative modality. To our knowledge, this is the first reported case of MPAL presenting with CES at disease onset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed the clinical data of a 21-year-old man with high-risk myeloid\/B-lymphoid MPAL presenting with CES as the initial manifestation. The patient initially presented with lumbosacral radicular pain and lower limb numbness, which rapidly progressed to fecal and urinary incontinence and inability to ambulate. Comprehensive imaging examinations and sacral biopsy ultimately confirmed myeloid\/pre-B lymphoblastic MPAL with cauda equina and lumbosacral nerve root involvement. After the patient achieved complete remission with the combination chemotherapy regimen (MTRix + VD + BCL-2i), which features high blood\u2013nerve-barrier penetration, the patient received myeloablative conditioning based on fractionated total-body irradiation and then underwent matched unrelated donor allo-HSCT. Third-party umbilical cord blood stem cells (UCBs) and mesenchymal stem cells (MSCs) were administered as adjunctive support. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine A, mycophenolate mofetil, and short-course methotrexate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Neutrophil and platelet engraftment occurred on days +12 and +10 post-transplant, respectively. At the 24-month follow-up, the patient remained in minimal residual disease (MRD)-negative remission of the primary disease, free of acute and chronic GVHD, with motor strength recovery from grade 0 to grade 3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In conclusion, evidence-based multi-agent chemotherapy followed by allo-HSCT with third-party UCBs and MSC support resulted in favorable engraftment kinetics, adequate GVHD prophylaxis, and long-term remission. These outcomes support its clinical application. These findings highlight the promising efficacy and safety of this combined treatment approach in this high-risk MPAL case.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1859413","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:28:56Z","timestamp":1789532936000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Successful treatment of mixed-phenotype acute leukemia with cauda equina syndrome as the initial manifestation"],"prefix":"10.3389","volume":"16","author":[{"given":"Xin","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, the First Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiology, the First Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqun","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangnian","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0058-4","article-title":"Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis","volume":"32","author":"Maruffi","year":"2018","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-314682","article-title":"Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification","volume":"117","author":"Matutes","year":"2011","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-551465","article-title":"How I treat mixed-phenotype acute leukemia","volume":"125","author":"Wolach","year":"2015","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/CMAR.S125259","article-title":"Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia","volume":"9","author":"Alakel","year":"2017","journal-title":"Cancer Manag Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02701-3","article-title":"Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations","volume":"60","author":"Greco","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00264-021-05273-1","article-title":"Cauda equina syndrome-a practical guide to definition and classification","volume":"46","author":"Lavy","year":"2022","journal-title":"Int Orthop"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2019.11.068","article-title":"Cauda equina syndrome secondary to diffuse infiltration of the cauda equina by acute myeloid leukemia: case report and literature review","volume":"134","author":"Walton","year":"2020","journal-title":"World Neurosurg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2023.01.002","article-title":"Characterization of the structure and control of the blood-nerve barrier identifies avenues for therapeutic delivery","volume":"58","author":"Malong","year":"2023","journal-title":"Dev Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26436","article-title":"Venetoclax combined with FLAG-based chemotherapy induces an early and deep response in mixed-phenotype-acute leukemia","volume":"97","author":"Segot","year":"2022","journal-title":"Am J Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3109\/07357909809115784","article-title":"Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation","volume":"1","author":"Deeg","year":"1986","journal-title":"Bone Marrow Transplant"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2024.103042","article-title":"Umbilical cord blood hematopoietic cells: from biology to hematopoietic transplants and cellular therapies","volume":"55","author":"Mayani","year":"2024","journal-title":"Arch Med Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41392-024-01820-5","article-title":"Haploidentical hematopoietic cell transplantation with or without an unrelated cord blood unit for adult acute myeloid leukemia: a multicenter, randomized, open-label, phase 3 trial","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00372-7","article-title":"Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological Malignancies: an open-label, multicentre, randomised, phase 3 trial","volume":"12","author":"Yu","year":"2025","journal-title":"Lancet Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019493","article-title":"The International Consensus Classification of acute leukemias of ambiguous lineage","volume":"141","author":"Weinberg","year":"2023","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"10S","DOI":"10.1177\/21925682231183969","article-title":"A clinical practice guideline on the timing of surgical decompression and hemodynamic management of acute spinal cord injury and the prevention, diagnosis, and management of intraoperative spinal cord injury: introduction, rationale, and scope","volume":"14","author":"Tetreault","year":"2024","journal-title":"Global Spine J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/0090-3019(88)90211-x","article-title":"Spinal cord involvement as the presenting symptom of acute monocytic leukemia","volume":"30","author":"Sugar","year":"1988","journal-title":"Surg Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810115)47:2<346::aid-cncr2820470223>3.0.co;2-u","article-title":"Spinal cord involvement in leukemia: a review of the literature and a case of Ph1+ acute myeloid leukemia presenting with a conus medullaris syndrome","volume":"47","author":"Petursson","year":"1981","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s0303-8467(98)00021-3","article-title":"Granulocytic sarcoma presenting as cauda equina syndrome","volume":"100","author":"Sandhu","year":"1998","journal-title":"Clin Neurol Neurosurg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.5858\/2001-125-1385-PQC","article-title":"Cauda equina syndrome in a 65-year-old man, status post-bone marrow transplant for chronic myeloid leukemia","volume":"125","author":"Dalton","year":"2001","journal-title":"Arch Pathol Lab Med"},{"key":"B20","article-title":"Cauda equina syndrome as a rare manifestation of leukemia relapse during postallograft period","volume":"98","author":"Onal","year":"2006","journal-title":"J Natl Med Assoc"},{"key":"B21","article-title":"Cauda equina involvement in acute myeloid leukemia relapse","volume":"94","author":"Buakhao","year":"2011","journal-title":"J Med Assoc Thai"},{"key":"B22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11060-008-9679-1","article-title":"Myeloid sarcoma presenting as a recurrent, multifocal nerve root entrapment syndrome","volume":"91","author":"Verra","year":"2009","journal-title":"J Neuro-Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200502","article-title":"Teaching NeuroImage: Thickened and enhanced cauda equina as a manifestation of acute lymphoblastic leukemia relapse","volume":"98","author":"Li","year":"2022","journal-title":"Neurology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1667681","article-title":"Isolated central nervous system relapse in acute myeloid leukemia: a case report and review of therapeutic challenges","volume":"15","author":"Burns","year":"2025","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00264-018-4208-0","article-title":"Cauda equina syndrome-the questions","volume":"43","author":"Quaile","year":"2019","journal-title":"Int Orthop"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026273","article-title":"Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype","volume":"145","author":"Galera","year":"2025","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287793","article-title":"Acute leukemia of ambiguous lineage: the known and the uncertain","volume":"111","author":"Sherban","year":"2026","journal-title":"Haematologica"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn121090-20241210-00554","article-title":"Safety and efficacy of mitoxantrone liposome combined chemotherapy in the treatment of mixed phenotype acute leukemia","volume":"46","author":"Jiang","year":"2025","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70491","article-title":"Improved survival with fludarabine-based therapies in mixed phenotype acute leukaemia: a population-based study using the WHO 2022 classification","volume":"208","author":"Christensen","year":"2026","journal-title":"Br J Haematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287932","article-title":"Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell\/myeloid mixed phenotype acute leukemia","volume":"110","author":"Azevedo","year":"2025","journal-title":"Haematologica"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1693061","article-title":"Case report: Venetoclax combined with hypomethylating agents for the treatment of newly diagnosed with mixed-phenotype acute leukemia and a literature review","volume":"15","author":"Mi","year":"2025","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70006","article-title":"Paired comparisons of venetoclax concentration in cerebrospinal fluid, bone marrow, and plasma in acute leukemia patients","volume":"17","author":"Jian","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.7150\/jca.81795","article-title":"Venetoclax penetrates the blood brain barrier: a pharmacokinetic analysis in pediatric leukemia patients","volume":"14","author":"Badawi","year":"2023","journal-title":"J Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00117-5","article-title":"Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial","volume":"10","author":"Xuan","year":"2023","journal-title":"Lancet Haematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104770","article-title":"Secondary mutational and cytogenetic alterations in core binding factor - acute myeloid leukemia (CBF-AML): a systematic review and meta-analysis","volume":"212","author":"Javidan","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/bjh.16092","article-title":"Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological Malignancies","volume":"187","author":"Weisberg","year":"2019","journal-title":"Br J Haematol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.70331","article-title":"Kinetic fingerprints as mechanistic and clinical roadmaps across KIT activation states","volume":"21","author":"Corrionero","year":"2026","journal-title":"ChemMedChem"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000788","article-title":"CNS involvement at initial diagnosis and risk of relapse after allogeneic HCT for acute lymphoblastic leukemia in first complete remission","volume":"6","author":"Kharfan-Dabaja","year":"2022","journal-title":"Hemasphere"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02280-9","article-title":"Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale propensity score matching-based study","volume":"59","author":"Shen","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.10.003","article-title":"Total body irradiation-based versus chemotherapy-alone myleloblative conditioning regimen before hematopoietic allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia: a multi-institutional study from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"124","author":"Belkacemi","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61091503","article-title":"Total body irradiation in haematopoietic stem cell transplantation: a comprehensive literature review and institutional experience from the Policlinico of Catania","volume":"61","author":"Lo Greco","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)00446-r","article-title":"Fractionated or single-dose total body irradiation in 171 acute myeloblastic leukemias in first complete remission: is there a best choice? SFGM. Societe Francaise de Greffe de Moelle","volume":"31","author":"Resbeut","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B44","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1186\/s13287-022-03170-x","article-title":"Unrelated umbilical cord blood can improve the prognosis of haploidentical hematopoietic stem cell transplantation","volume":"13","author":"Yang","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05399-9","article-title":"Quadruple stem cells transplantation of haploidentical bone marrow and PBSCs supporting by third-party umbilical cord blood and MSCs achieved excellent outcomes","volume":"102","author":"Luo","year":"2023","journal-title":"Ann Hematol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2011.12.015","article-title":"The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation","volume":"73","author":"Luevano","year":"2012","journal-title":"Hum Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01635.x","article-title":"Xenogeneic immunosuppression of human umbilical cord mesenchymal stem cells in a major histocompatibility complex-mismatched allogeneic acute graft-versus-host disease murine model","volume":"87","author":"Guo","year":"2011","journal-title":"Eur J Haematol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s13287-024-03947-2","article-title":"Concurrent hypoxia and apoptosis imparts immune programming potential in mesenchymal stem cells: lesson from acute graft-versus-host-disease model","volume":"15","author":"Mendiratta","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001074","article-title":"Advancements and mechanisms of stem cell-based therapies for spinal cord injury in animals","volume":"110","author":"Mili","year":"2024","journal-title":"Int J Surg"},{"key":"B50","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s13287-022-02875-3","article-title":"Mesenchymal stromal cell-derived extracellular vesicles: novel approach in hematopoietic stem cell transplantation","volume":"13","author":"Sarvar","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO-24-02119","article-title":"Sequential infusion of mesenchymal stem cell for graft-versus-host disease prevention in haploidentical hematopoietic stem cell transplantation: An open-label, multicenter, randomized controlled clinical trial","volume":"43","author":"Yao","year":"2025","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.801851","article-title":"Minimal residual disease assessment in multiple myeloma patients: Minimal disease with maximal implications","volume":"11","author":"Charalampous","year":"2021","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1859413\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:29:02Z","timestamp":1789532942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1859413\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":52,"alternative-id":["10.3389\/fonc.2026.1859413"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1859413","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1859413"}}